PCNT as a target protein for treatment or diagnosis of brain-nervous system diseases
US12274717B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2018 |
| Grant date | Apr 15, 2025 |
| Priority date | — |
| Expiry date | Jan 12, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a pharmaceutical composition for preventing or treating a central nervous system disease including, as an active ingredient, cord blood or cord blood-derived cells expressing or secreting pericentrin (PCNT), a composition or kit for diagnosing a central nervous system disease including an agent for measuring a level of PCNT protein, a method of analyzing information required for diagnosing a central nervous system disease using PCNT protein, and a method of screening a candidate substance for a therapeutic agent to treat a central nervous system disease. By using the composition including cord blood or cord blood-derived cells expressing or secreting PCNT, central nervous system diseases may be efficiently prevented or treated. Furthermore, the PCNT protein may be used as a target for diagnosing a central nervous system disease at an early stage and for developing a therapeutic agent for a central nervous system disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.